Amylin + GLP-1 Combination
Amylin + GLP-1 Dual Agonist
Best For
Clients seeking maximum weight loss support through complementary receptor pathways
Dual
Body weight studied in the REDEFINE trial program
2
Complementary satiety pathways engaged
Phase 3
Clinical development stage (REDEFINE program)
How It Works
This combination pairs a long-acting amylin analogue acting on the area postrema to promote satiety with a first-generation GLP-1 for incretin-mediated appetite suppression and metabolic improvement. These dual pathways are studied for additive effects on body weight. Phase 3 trials in the REDEFINE program examine total body-weight outcomes.
Key Research Areas
Dual Pathway Activation
Engages both amylin and GLP-1 signaling for complementary appetite control
Body-Weight Research
Studied in Phase 3 (REDEFINE) for body-weight outcomes vs. single-agent therapy
Metabolic Improvement
The first-generation GLP-1 component enhances insulin sensitivity and glucose regulation
Satiety Enhancement
The amylin analogue targets brainstem satiety centers independent of incretin pathways
Research Highlights
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Featured Research
Formulation Notes
Common concentrations referenced in published clinical studies:
[CS10]10mg (Amylin 5mg + GLP-1 5mg)Category
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
First-Generation GLP-1
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgAmylin Analogue
Long-Acting Amylin Analogue
- Amylin-pathway satiety — complementary to GLP-1 receptor agonists
- Long-acting acylated design supports convenient once-weekly dosing
Reference Codes
[CGL5]5mg[CGL10]10mgSecond-Generation GLP-1
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgEvidence reviewed: March 2026